Abstract:Background: G-protein coupled receptor 34 (GPR34) is involved in cell motility, differentiation, and mitosis. GPR34 was reported to be highly expressed and play an oncogenic role in several solid tumors. Here, we investigated the mechanisms underlying how GPR34 promotes glioma progression. Methods: Bioinformatic analysis was performed on RNA-seq and clinical data from the gene expression omnibus (GEO), cancer genome atlas (TCGA), and Genotype-Tissue Expression (GTEx) databases. TIMER database and single-sample GSEA (ssGAEA) method were used to investigate the association between the GPR34 expression and immune infiltration level in glioma. Cox regression analysis was employed to ascertain whether the risk signature was an independent prognostic indicator for glioma. The viability and migratory/invasive potential of glioma cells were assessed using Cell Counting Kit-8, colony formation, wound healing, and Transwell assays. Results: We found that GPR34 expression was positively correlated with immune infiltration level and that high GPR34 level may be associated with poor prognosis in glioma. We further found that GPR34 may serve as an independent prognostic marker and prediction factor for the clinicopathological features of glioma. We showed that knocking down GPR34 attenuated the viability and migratory/invasive capacity of glioma cells (U251 and LN229), while GPR34 overexpression exerted the opposite effects. Additionally, core enrichment in the GSEA analysis indicated that GPR34-mediated gliomagenesis was associated with the cell cycle arrest, epithelial-mesenchymal transition (EMT), and activation of the TGF-β/Smad pathway; furthermore, inhibiting TGF-β/Smad signaling using LY2157299, a TGF-β inhibitor, reversed the oncogenic effects and malignant phenotype associated with GPR34 overexpression. Conclusion: GPR34 enhances the malignancy and carcinogenesis of glioma by promoting an EMT-like process, G1/S phase cell cycle transition, and TGF-β/Smad signaling. Accordingly, GPR34 likely functions as an oncogene in glioma and may represent a potential therapeutic target for this cancer.

Inhibition of Gpr137 Expression Reduces the Proliferation and Colony Formation of Malignant Glioma Cells

Influence of Small Interfering RNA-mediated Inhibiting Human Runt-Related Transcription Factor 2 and Galectin-3 Gene on Proliferation and Apoptosis of Glioma Cell U251

Overexpressed Mirna-137 Inhibits Human Glioma Cells Growth by Targeting Rac1

MicroRNA-137 inhibits growth of glioblastoma through EGFR suppression.

GliPR1 knockdown by RNA interference exerts anti‐glioma effects in vitro and in vivo

Suppressive effect of miR-137 on proliferation and apoptosis of U87 glioma cells in vitro

Inhibition of EGR1 Inhibits Glioma Proliferation by Targeting CCND1 Promoter

Long Noncoding RNA Lncherg Promotes Cell Proliferation, Migration and Invasion in Glioblastoma

Mir-138-5p Suppresses Glioblastoma Cell Viability and Leads to Cell Cycle Arrest by Targeting Cyclin D3.

G-protein-coupled receptor GPR17 inhibits glioma development by increasing polycomb repressive complex 1-mediated ROS production

A Novel Gene RNF138 Expressed in Human Gliomas and Its Function in the Glioma Cell Line U251

Silencing of PRDM5 Increases Cell Proliferation and Inhibits Cell Apoptosis in Glioma

GPR27 expression correlates with prognosis and tumor progression in gliomas

GGNBP2 Suppresses the Proliferation, Invasion, and Migration of Human Glioma Cells.

Human corticotrophin releasing factor inhibits cell proliferation and promotes apoptosis through upregulation of tumor protein p53 in human glioma.

Knockdown of LGR5 Suppresses the Proliferation of Glioma Cells in Vitro and in Vivo.

miR-137 is frequently down-regulated in glioblastoma and is a negative regulator of Cox-2.

Silencing Myelin Protein Zero-Like 1 Expression Suppresses Cell Proliferation and Invasiveness of Human Glioma Cells by Inhibiting Multiple Cancer-Associated Signal Pathways

G-protein Coupled Receptor 34 Promotes Gliomagenesis by Inducing Proliferation and Malignant Phenotype via TGF-Beta/Smad Signaling Pathway

Glucose-regulated protein 94 is a novel glioma biomarker and promotes the aggressiveness of glioma via Wnt/β-catenin signaling pathway

The 37-Kda Laminin Receptor Precursor Regulates the Malignancy of Human Glioma Cells.